A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion. 1977

Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma

A double-blind multiclinic trial compared the efficacies of pyridinolcarbamate and inositol niacinate in the patients with the ischemic ulcer due to chronic arterial occlusion. A thrice-daily dose of 1.5 g of pyridinolcarbamate or 1.2 g of inositol niacinate was given at random to the patients during cold seasons, and the effectiveness of treatment was assessed mainly on the basis of the clinical course of the ischemic ulcer and the rest pain. The patients were classified into 4- and 6-week groups. Beneficial results were recorded in 16 of 32 cases (50.0%) of the 4-week pyridinolcarbamate group, and in 24 of 42 cases (57.1%) of the 4-week inositol niacinate group. In the 6-week group favorable results were observed in 54 of 79 cases (68.4%) on pyridinolcarbamate, and in 36 of 74 cases (48.6%) on inositol niacinate. Although sympathectomy is currently indicated for these ischemic lesions, long-term treatment with pyridinolcarbamate is recommended on the basis of the finding that the 6-week treatment appears superior to the 4-week treatment and also to the 6-week treatment with inositiol niacinate.

UI MeSH Term Description Entries
D007294 Inositol An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction. Myoinositol,Chiro-Inositol,Mesoinositol,Chiro Inositol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011727 Pyridinolcarbamate A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408) Pyricarbate,2,6-Pyridinedimethanol-bis-(N-methylcarbamate),Anginin,Angioxine,Colesterinex,Duaxol,Duvaline,Gasparol,Lisator,Movecil,P-23,Parmidine,Prodectin,Sospitan,P 23,P23
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005767 Gastrointestinal Diseases Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Cholera Infantum,Gastrointestinal Disorders,Functional Gastrointestinal Disorders,Gastrointestinal Disorders, Functional,Disease, Gastrointestinal,Diseases, Gastrointestinal,Functional Gastrointestinal Disorder,Gastrointestinal Disease,Gastrointestinal Disorder,Gastrointestinal Disorder, Functional

Related Publications

Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
April 1991, Zhonghua nei ke za zhi,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
February 1973, British heart journal,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
January 1972, Japanese heart journal,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
April 1969, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
October 1978, Gastroenterologie clinique et biologique,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
January 2018, Revista de gastroenterologia de Mexico (English),
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
April 1977, Psychopharmacology bulletin,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
January 1982, The Journal of international medical research,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
January 1981, The Journal of international medical research,
Y Mishima, and K Kamiya, and S Sakaguchi, and A Kusaba, and A Sakuma
May 1995, The American journal of psychiatry,
Copied contents to your clipboard!